XML 82 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborations and Other Arrangements (Narrative) (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
May 31, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Acquired IPR&D charges     $ 660.4 $ 239.6 $ 1,980.0
Revenue     24,539.8 22,319.5 21,493.3
Contract liabilities     276.8 264.6  
AbCellera Biologics Inc. (AbCellera)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Acquired IPR&D charges $ 25.0 $ 25.0 25.0    
Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Acquired IPR&D charges $ 20.0   20.0    
China          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     1,116.9 939.4 750.8
Milestone Payments, Success-based Regulatory And Sales-based | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Acquired IPR&D charges     50.0    
Milestone Payments, Sales-based | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     120.0    
Milestone Payments, Success-based Regulatory | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     75.0    
Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     $ 638.9 426.9 $ 202.5
Olumiant® | Royalty Payments Received          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, rights and obligations percent     20.00%    
Olumiant® | Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     $ 210.0 180.0  
Olumiant® | Milestone Payments, Development and Regulatory          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     100.0    
Olumiant® | Milestone Payments, Sales-based          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     150.0    
Bamlanivimab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     871.2    
Tyvyt          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue     308.7 $ 134.0  
Tyvyt | Milestone Payments, Success-based Regulatory And Sales-based | Outside of China | Innovent Biologics, Inc. (Innovent)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     825.0    
Tyvyt | Milestone Payments, Success-based Regulatory And Sales-based | China | Innovent Biologics, Inc. (Innovent)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     75.0    
Tanezumab | Outside US And Japan          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Annual net sales threshold (greater than)     150.0    
Tanezumab | Milestone Payments, Development and Regulatory          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     147.5    
Tanezumab | Milestone Payments, Sales-based          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     1,230.0    
Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Contract liabilities     29.7    
Lebrikizumab | Milestone Payments, Development and Regulatory          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     85.0    
Lebrikizumab | Milestone Payments, Development and Regulatory | Roche          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     180.0    
Lebrikizumab | Milestone Payments, Sales-based          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     1,250.0    
Lebrikizumab | Milestone Payments, Sales-based | Roche          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestones payments     $ 1,030.0